BrightPath Biotherapeutics Co.Ltd.

As of March 31, 2026, BrightPath Biotherapeutics Co.Ltd. carries a market capitalization of 9.58B, placing it among publicly traded companies globally. Its enterprise value stands at 7.43B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

BrightPath Biotherapeutics Co.Ltd.'s next confirmed earnings release is scheduled for November 13, 2026.

As of March 31, 2026, BrightPath Biotherapeutics Co.Ltd. has 138.89M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, BrightPath Biotherapeutics Co.Ltd. maintains a current ratio of 15.83, meaning it holds 15.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, BrightPath Biotherapeutics Co.Ltd.'s stock has declined approximately 40.30% over the past 52 weeks. The 50-day moving average sits at 50.74, while the 200-day moving average is 56.09.

As of March 31, 2026, BrightPath Biotherapeutics Co.Ltd. holds 2.16B in cash and equivalents against - - in total debt, resulting in a net debt position of -2.16B. Total book value stands at 2.37B, with working capital of 2.39B providing operational flexibility.